Selective Imidazopyrimidine Inhibitors for A2A/A2B Immune Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need to develop new adenosine receptor selective ligands, particularly for subtypes A2A and A2B, to treat diseases such as cancer, inflammatory diseases, and neurodegenerative diseases, as existing treatments do not effectively modulate immune responses and inhibit excessive immune reactions in tumor micro-environments.
Innovation Solution
Development of imidazopyrimidine and triazolopyrimidine compounds that selectively target A2A and A2B adenosine receptors, inhibiting their activity to modulate immune responses and treat associated diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If existing adenosine receptor ligands are used, then general adenosine signaling is modulated, but selective inhibition of A2A and A2B subtypes is not achieved, limiting therapeutic effectiveness
Solution Approach 1:
The patent applies local quality by designing ligands with specific molecular structures (imidazopyrimidine and triazolopyrimidine cores) that confer selective affinity for A2A and A2B adenosine receptors. The compounds exhibit differential binding characteristics that enable selective inhibition of specific receptor subtypes, thereby achieving the desired therapeutic selectivity while maintaining adaptability across different disease indications.
2Object-generated harmful factors
If non-selective adenosine receptor antagonists are used, then broad receptor activity is achieved, but excessive immune reactions cannot be effectively suppressed
Solution Approach 1:
The patent segments the adenosine receptor system into distinct A2A and A2B subtypes with different functional profiles. By developing selective ligands that target specific subtypes, the invention can suppress excessive immune reactions mediated by A2B receptors while preserving A2A-mediated protective functions, thereby improving reliability of immune response modulation.
Solution Approach 2:
The invention applies local quality by creating compounds with differentiated binding affinities for A2A and A2B receptors. The imidazopyrimidine and triazolopyrimidine compounds exhibit selective inhibition patterns that allow targeted suppression of harmful immune reactions through A2B blockade while maintaining A2A activity for protective immune regulation.
3Productivity
If A2B adenosine receptor activity is inhibited, then tumor growth is suppressed, but off-target effects on other receptor subtypes may occur
Solution Approach 1:
The patent applies local quality by designing compounds with selective pharmacological profiles that target A2B receptors specifically. The imidazopyrimidine and triazolopyrimidine ligands exhibit preferential binding to A2B over other adenosine receptor subtypes, enabling effective tumor growth inhibition while minimizing off-target effects on A1, A2A, and A3 receptors.
Data Source
AI summary
This application relates to compounds of Formula (I):or pharmaceutically acceptable salts or stereoisomers thereof, which modulate the activity of adenosine receptors, such as subtypes A2A and A2B receptors, and are useful in the treatment of diseases related to the activity of adenosine receptors including, for example, cancer, inflammatory diseases, cardiovascular diseases, and neurodegenerative diseases.